Market research
LEGN Legend Biotech Corp
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 4B
- P/E ratio
- Not available
- Analyst target
- 49.2467
- Dividend yield
- Not available
- Beta
- 0.39
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US52490G1022
- Market cap
- 4B
- P/E ratio
- Not available
- Analyst target
- 49.2467
- Dividend yield
- Not available
- Beta
- 0.39
About
About Legend Biotech Corp
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the LEGN discussion.
5 years, 4 months ago
Legend Biotech Corporation is currently in a long term uptrend where the price is trading 30.4% above its 200 day moving average.
From a valuation standpoint, the stock is 96.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 47.0.
Legend Biotech Corporation's total revenue rose by 109.7% to $41M since the same quarter in the previous year.
Its net income has increased by 9.6% to $-58M since the same quarter in the previous year.
Finally, its free cash flow fell by 2.6% to $-102M since the same quarter in the previous year.
Based on the above factors, Legend Biotech Corporation gets an overall score of 4/5.